Emoxy-Optic (Emoxipine) Eye Drops 1%, 5 ml
- $3.20
Eye drops 1%
Active nigredient -1 ml of methylethylpyridinol hydrochloride (emoxipine) 10 mg.
Excipients: anhydrous sodium sulfite, sodium benzoate, potassium dihydrogen phosphate (potassium phosphate monosubstituted), sodium hydrogen phosphate dodecahydrate (disubstituted sodium phosphate 12-aqueous), methylcellulose, water for injections.
An antioxidant product that prevents lipid peroxidation of cell membranes. It has angioprotective, antiaggregant and antihypoxic activity.
Reduces capillary permeability and strengthens the vascular wall (angioprotective effect). Reduces blood viscosity and platelet aggregation (antiplatelet action). Inhibits the formation of free radicals (antioxidant action). It has a membrane stabilizing effect. Increases tissue resistance to oxygen deficiency (antihypoxic effect).
It has retinoprotective properties, protects the retina and other eye tissues from the damaging effects of high-intensity light. Promotes resorption of intraocular hemorrhages, reduces blood clotting, improves microcirculation of the eye. Stimulates reparative processes in the cornea (including in the early postoperative and postoperative period).
Distribution
It quickly penetrates into organs and tissues, where it is deposited and metabolized. In the tissues of the eye, the concentration is higher than in the blood.
Metabolism
Found 5 metabolites represented by dealkylated and conjugated transformation products. Metabolites are excreted by the kidneys. Significant amounts of 2-ethyl-6-methyl-3-oxypyridine-phosphate are found in the liver tissue.
The drug Emoxy-optic is prescribed for adults. Buried in the conjunctival sac 1-2 drops 2-3
The course of treatment is 3-30 days. If necessary and well tolerated, the course of treatment can be continued up to 6 months and can be repeated 2-3 times a year.
Local reactions: burning sensation, itching, short-term hyperemia of the conjunctiva; not often - local allergic reactions.
Pregnancy and lactation
The drug is contraindicated during pregnancy and lactation (breastfeeding).
If necessary, the simultaneous use of other eye drops, the product is instilled in the aftermath, after the complete absorption of the previous drops (at least 10-15 minutes later).
An overdose of the product Emoxy-optic has not been established.
Emoxy Optic should not be mixed with other medicinal products.
The drug should be stored out of the reach of children, protected from light at a temperature not exceeding 25 ° C. Shelf life - 2 years.
After opening the vial, the product should be used within 1 month.
Active nigredient -1 ml of methylethylpyridinol hydrochloride (emoxipine) 10 mg.
Excipients: anhydrous sodium sulfite, sodium benzoate, potassium dihydrogen phosphate (potassium phosphate monosubstituted), sodium hydrogen phosphate dodecahydrate (disubstituted sodium phosphate 12-aqueous), methylcellulose, water for injections.
Pharmachologic effect
An antioxidant product that prevents lipid peroxidation of cell membranes. It has angioprotective, antiaggregant and antihypoxic activity.
Reduces capillary permeability and strengthens the vascular wall (angioprotective effect). Reduces blood viscosity and platelet aggregation (antiplatelet action). Inhibits the formation of free radicals (antioxidant action). It has a membrane stabilizing effect. Increases tissue resistance to oxygen deficiency (antihypoxic effect).
It has retinoprotective properties, protects the retina and other eye tissues from the damaging effects of high-intensity light. Promotes resorption of intraocular hemorrhages, reduces blood clotting, improves microcirculation of the eye. Stimulates reparative processes in the cornea (including in the early postoperative and postoperative period).
Pharmacokinetics
Distribution
It quickly penetrates into organs and tissues, where it is deposited and metabolized. In the tissues of the eye, the concentration is higher than in the blood.
Metabolism
Found 5 metabolites represented by dealkylated and conjugated transformation products. Metabolites are excreted by the kidneys. Significant amounts of 2-ethyl-6-methyl-3-oxypyridine-phosphate are found in the liver tissue.
Indications for use of the Emoxy-Optic
- hemorrhages in the anterior chamber of the eye (treatment);
- hemorrhages in the sclera in the elderly (treatment and prevention);
- inflammation and burns of the cornea (treatment and prevention);
- complications of myopia (treatment);
- corneal protection (when wearing contact lenses)
Dosing regimen
The drug Emoxy-optic is prescribed for adults. Buried in the conjunctival sac 1-2 drops 2-3
The course of treatment is 3-30 days. If necessary and well tolerated, the course of treatment can be continued up to 6 months and can be repeated 2-3 times a year.
Possible side effect
Local reactions: burning sensation, itching, short-term hyperemia of the conjunctiva; not often - local allergic reactions.
Contraindications
- pregnancy;
- lactation period (breastfeeding);
- children and adolescents up to 18 years of age;
- hypersensitivity to the components of the product.
Pregnancy and lactation
The drug is contraindicated during pregnancy and lactation (breastfeeding).
Special instructions
If necessary, the simultaneous use of other eye drops, the product is instilled in the aftermath, after the complete absorption of the previous drops (at least 10-15 minutes later).
Overdose
An overdose of the product Emoxy-optic has not been established.
Drug interaction
Emoxy Optic should not be mixed with other medicinal products.
Storage conditions
The drug should be stored out of the reach of children, protected from light at a temperature not exceeding 25 ° C. Shelf life - 2 years.
After opening the vial, the product should be used within 1 month.
Related Products
Recently Viewed
